As part of Medicine Australia’s five-year Strategic Agreement with the Federal Government, an independent review of Australia’s health technology assessment (HTA) system is being undertaken – the first of its kind in nearly 30 years.
HTA reform will ensure that Australia’s HTA system evolves to keep pace with advancements in medical technologies and delivers faster access to new medicines for patients.
Next steps
The HTA Policy and Methods Review Reference Committee has been considering stakeholder feedback collected through Consultation 1. This feedback, in addition to HTA expert papers, has been used to develop an Options Paper detailing options for reform. The Options Paper will be workshopped with stakeholders through a second round of public consultation (Consultation 2).
Consultation 2 opened for submissions on 22 January 2024 with online and in-person workshops planned to take place throughout February 2024.
As the national peak body for Australians living with a rare disease, Rare Voices Australia will continue participating in the consultation process throughout the Health Technology Assessment Policy and Methods Review.
The Options Paper for Consultation 2 is now available via the Office of Health Technology Assessment’s (OHTA) consultation hub.
